{
    "eid": "2-s2.0-84987910762",
    "title": "Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment",
    "cover-date": "2016-08-08",
    "subject-areas": [
        {
            "$": "Oncology",
            "@code": "2730"
        }
    ],
    "keywords": [
        "Antihormone",
        "CYP450",
        "Oncology",
        "Pharmacogenetics",
        "Pharmacogenomics",
        "SNPs"
    ],
    "authors": [
        "Wanaporn Charoenchokthavee"
    ],
    "citedby-count": 9,
    "ref-count": 26,
    "ref-list": [
        "PharmGKB summary: Tamoxifen pathway, pharmacokinetics",
        "Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer",
        "CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients",
        "Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer",
        "CYP2D6 Genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial",
        "Pharmacogenomics of breast cancer therapy: An update",
        "Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry",
        "Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen",
        "Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen",
        "CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis",
        "CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations",
        "Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes",
        "Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer",
        "Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients",
        "The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1",
        "Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients",
        "Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer",
        "Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase i and II enzymes on their concentration levels in plasma",
        "Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: Effect on active metabolite isomers and the antiestrogenic activity score",
        "CYP2D6 genotype and tamoxifen activity: Understanding interstudy variability in methodological quality",
        "Tamoxifen and CYP2D6: A contradiction of data",
        "Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation",
        "Pharmacogenomics of CYP2D6: Molecular genetics, interethnic differences and clinical importance",
        "Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients",
        "Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy",
        "Complexities of CYP2D6 gene analysis and interpretation"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hat Yai, Songkhla",
            "affilname": "Faculty of Pharmaceutical Sciences",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}